Document Detail


Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
MedLine Citation:
PMID:  19998574     Owner:  HSR     Status:  MEDLINE    
Abstract/OtherAbstract:
Access to prescription medicines is an essential component of publicly funded or publicly assisted healthcare programs. Thus, important policy questions are presented when government agencies that administer those programs establish procedures for making decisions about the appropriate use of medicines, including determinations as to which medicines will be reimbursed, at what prices, and for which patients. The authors reviewed systems for making determinations on pricing and reimbursement of prescription medicines under public healthcare systems in 10 countries, including four member states of the European Union (EU) (France, Germany, Italy and the United Kingdom), plus Australia, Brazil, China, India, Japan and Korea. In addition to national regulatory requirements, the authors considered international agreements that may impose obligations with respect to procedures for pricing and reimbursement of prescription medicines, including the EU's Transparency Directive, agreements administered by the World Trade Organization (WTO), and bilateral free trade agreements negotiated by the United States in recent years. Drawing on this experience, the authors sought to identify common themes, pitfalls and best practices in national systems for regulating pricing and reimbursement of prescription medicines. The authors have focused primarily on procedures, rather than the underlying political assumptions or substantive economic objectives. They have assumed that all countries have--or should have--a common interest in assuring that decision-making procedures afford interested persons who have relevant information a meaningful opportunity to participate
Authors:
Richard Kingham; Joanna Wheeler
Related Documents :
20188324 - Community pharmacists' prescription intervention practices--exploring variations in pra...
19630844 - Increased patient co-payments and changes in pbs-subsidised prescription medicines disp...
25150944 - Clinical trials of integrative medicine: testing whether magic works?
22557374 - Self - realization through through vedanta and yoga.
23002284 - Immunohistochemistry in the era of personalised medicine.
21620764 - Cytomegalovirus quantification: where to next in optimising patient management?
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Food and drug law journal     Volume:  64     ISSN:  1064-590X     ISO Abbreviation:  Food Drug Law J     Publication Date:  2009  
Date Detail:
Created Date:  2009-12-09     Completed Date:  2009-12-22     Revised Date:  2010-01-13    
Medline Journal Info:
Nlm Unique ID:  9215384     Medline TA:  Food Drug Law J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  101-14     Citation Subset:  T    
Affiliation:
Covington & Burling LLP, Washington, DC, USA, and London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Asia
Australia
Commerce
Decision Making
Disclosure
Europe
European Union
Government Regulation*
Humans
Insurance, Health, Reimbursement*
Patient Participation
Prescription Drugs / economics*
Rate Setting and Review / organization & administration*
United States
Chemical
Reg. No./Substance:
0/Prescription Drugs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pandemic influenza: is there a corporate duty to prepare?
Next Document:  Memory improving and antidepressant effects of topiramate in rats.